Skip to main content
. 2022 Mar 16;13:1380. doi: 10.1038/s41467-022-28907-3

Fig. 7. Indisulam is efficacious in IMR-32 neuroblastoma in vivo xenografts.

Fig. 7

a Tumour growth in mice bearing IMR-32 xenografts treated with either vehicle (n = 5) or indisulam (n = 5) for 8 days. Tumour volume measured every 2–3 days until the humane end-point was reached. b Waterfall plot showing relative changes in tumour volume of xenografts at Day 7. c Survival plot of mice bearing IMR-32 xenografts. d Representative images of IMR-32 xenografts treated with vehicle (Day 22) or indisulam (Day 8). e Immunofluorescent staining of RBM39 and Ki67 in IMR-32 xenograft bearing mice treated with vehicle or indisulam after 4 days. The scale bar is 20 µm f. PCR of CDK4 in IMR-32 xenograft tumour treated with vehicle or indisulam. g. PCR of TRIM27 in IMR-32 xenograft tumour treated with vehicle or indisulam. h. Volcano plot of metabolites in IMR-32 xenograft tissues detected by LC-MS (HILIC method). i. Glycine and serine changes were detected in xenograft tumours (n = 5 samples per group). Data are presented as mean ± SEM. Statistical analysis in i and j was determined by a two-tailed unpaired t-test. Source data is provided as a Source Data File.